Table 3 Univariate and multivariate analyses of cancer free survival using the Cox proportional-hazard regression.

From: Superpixel image segmentation of VISTA expression in colorectal cancer and its relationship to the tumoral microenvironment

Variable

Univariant

CI

P-value

Multivariant

CI

P-value

VISTA Manual analysis

0.331

0.130–0.845

0.021

–

–

–

≤ 20%

      

> 20%

      

VISTA Superpixel analysis

0.262

0.103–0.668

0.005

0.95

0.902–0.987

0.006

≤ 20%

      

> 20%

      

Age

1.024

0.990–1.050

0.062

0.989

0.955–1.024

0.524

≤ 70

      

> 70

      

Gender

1.077

0.587–1.976

0.810

1.325

0.652–2.693

0.438

Male

      

Female

      

Pre-surgery chemotherapy

1.601

0.872–2.941

0.129

1.513

0.813–2.815

0.191

No therapy

      

Complete regression

      

Partial regression

      

No regression

      

Pre-cancer condition

0.985

0.866–1.119

0.814

1.014

0.890–1.157

0.830

Non

      

TA

      

VA

      

TVA

      

SSA

      

AJCC stage

2.114

1.312–10.62

0.038

35.235

8.926–39.089

0.001

I/II

      

III/IV

      

Pathologic stage

5.619

1.352–23.356

0.018

7.306

1.645–32.452

0.009

PT1

      

PT2

      

PT3

      

PT4

      

Lymph node stage

1.091

0.698–1.704

0.702

1.156

0.687–1.945

0.586

N0

      

N1-2

      

Tumor grade

1.442

0.730–2.851

0.292

2.405

0.883–4.736

0.095

G1-G2

      

G3

      

Tumor budding

2.180

1.638–3.281

0.048

1.180

0.564–2.469

0.660

TBD1

      

TBD2 or TBD3

      

LVI

1.946

1.007–3.763

0.048

1.356

0.921–4.342

0.072

Not present

      

Present

      

TIL

1.010

0.533–1.911

0.977

2.045

0.883–4.736

0.095

Low

      

High

      

Stromal differentiation

3.062

1.342–6.989

0.008

3.990

1.604–9.924

0.003

Immature

      

Mature

      

MMR (IHC)

0.823

0.404–1.678

0.593

1.679

0.599–4.707

0.325

All positive

      

Loss of MLH1/PMS2

      

Loss of MLH1 only

      

Loss of PMS 2 only

      

Loss of MSH2/MSH6

      

Loss of MSH2 only

      

Loss of MSH6 only

      
  1. HR hazard ratio, VISTA V-domain immunoglobulin suppressor of T cell activation, TBD tumor budding grade, PT stage, N nodal stage, LVI lymph-vascular invasion, TIL tumor-infiltrating lymphocytes, G grade, MMR mis-match repair. Significant features (P ≤ 0.05) are shown in bold.
Back to article page